drugset / Trial / NCT05400746
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is an open label, single-site, first-in-human, dose-escalation Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs48/45 in Matrix-M adjuvant in healthy adults living in the UK
Timeline
- Start
- 2022-11-02
- Primary completion
- 2023-10-19
- Completion
- 2023-10-19
Outcome
Outcome not reported
Stopped (Enrollment): “Significant delays in vaccine adjuvant supply due to an out of specification within the context of the grant timeline. Limited safety and immunological data could be accrued from incomplete regimens.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pfs48/45 | Vaccine | 10 ug | Intramuscular |
| Subject | Pfs48/45 | Vaccine | 50 ug | Intramuscular |
| Background | Matrix-M1 Adjuvant | Other / unclassified | 50 ug | Intramuscular |